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1. Introduction 
Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder, present in 
5 – 7% of women of reproductive age. The diagnosis of PCOS was made according to 
Rotterdam criteria in presence of at least two of the following: 1) oligomenorrhea and/or 
anovulation; 2) hyperandrogenism (clinical and/or biochemical); 3) polycystic ovaries with the 
exclusion of other etiologies (1). The disorder is characterized by irregular menstrual cycle, 
chronic anovulation and hyperandrogenism. Women with PCOS demonstrate marked clinical 
heterogeneity: the commonly associated features of hirsutism, acne, polycystic-appearing 
ovaries, obesity and acanthosis nigricans are neither uniform nor universal (2-3). In time the 
disorder may lead to onset of hyperinsulinemia, insulin resistance, gestational diabetes, early 
onset of type 2 diabetes mellitus (DM), dyslipidemia and cardiovascular disease (CVD) (4-5). 
PCOS is characterized by a complex physiology implicating an interaction with 
environmental and genetic factors, resulting in a broad spectrum of reproductive and 
metabolic disorders. (6-7) Adult females with PCOS may be at increased risk for 
atherosclerotic cardiovascular disease (CVD) due to increased prevalence of obesity and 
central adiposity as well as to hypertension, hyperinsulinemia, type 2 DM, and dyslipidemia 
in these patients (8).The prevalence of obesity and consequently the presence of metabolic 
abnormalities reported in Italian and American published studies differs considerably, 
underlining the presence of important ethnic differences. (9, 10, 11, 12). 
A percentage ranging from 30-75% of women with PCOS are obese, European women 
generally weighing less than their American counterparts (20,21). Hyperinsulemia and/or 
insulin resistance (IR) are frequently manifested in obese, and to a lesser extent (50%) in 
lean, PCOS patients (3, 13, 14). Hyperandrogenaemia, hyperinsulemia and obesity are 
considered as risk factors for the development of hypertension and dyslipidemia, diabetes 
mellitus and coronary disease in PCOS (15-16). The causes of metabolic disorders in PCOS 
remain to be clarified, but include obesity-related IR, an intrinsic abnormality of 
postreceptor insulin signaling (e.g. excess serine phosphorylation), and abnormal insulin 
secretion. On the other hand, increased resistance to insulin is a hallmark of the onset of 
normal pubertal development with natural to pre-pubertal values at the end of puberty in 
non-obese subjects. Consequently, in early adolescence a physiological resistance to insulin 
should be taken into account (12). 
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Dyslipidemia in PCOS is frequently manifested and is characterized by elevated plasma 
levels of low- density lipoproteins (LDL), very-low-density lipoproteins (VLDL) and 
triglycerides with concomitantly reduced concentration of high-density lipoproteins (HDL) 
in obese subjects (17, 18). A decrease in HDL, rise in triglyceride, VLDL, and LDL levels, as 
well as qualitative disorders of the LDL have all been described in young and adult PCOS 
(19). Moreover, recent data have shown a higher prevalence of metabolic syndrome in 
adolescent PCOS compared to controls (20) as well as an early impairment of endothelial 
structure and function even in non-dyslipidemic subjects with PCOS syndrome (21). 
Nevertheless, metabolic disorders in PCOS have not been extensively studied in the 
adolescent population. Several studies have shown how both lean and obese adolescents 
with PCOS appear to present an increased risk of both metabolic disorders and impaired 
glucose tolerance and diabetes (22), similar to their adult counterparts. A previous study 
carried out by our group demonstrated that the Italian young PCOS population is 
characterized by a high incidence of insulin alterations also in presence of normal weight 
and normal peripheral insulin resistance (12). Although the prevalence of dyslipidemia 
differs between PCOS subjects and young healthy girls, it however remains to be clarified 
whether dissimilarities in dyslipidemia occur in relation only to BMI or also to alterations to 
the insulinmetabolism and/or hyperandrogenemia. 
Carmina recently demonstrated that MBS in women with PCOS is less common in Southern 
Italy compared to rates reported in the USA, the former reaching only 8.2% compared to a 
prevalence of 43-46% reported by US authors (23). The prevalence of MBS in the adult 
Italian PCOS population is higher than in control population matched for BMI, suggesting 
that body weight may be only in part responsible for this metabolic disorder (24). 
Although few studies have investigated the latter condition in adolescents, it could prove to 
be of considerable importance in view of the health implications involved, requiring medical 
counseling to implement an adequate change in lifestyle. Likewise, obesity rate in 
adolescent PCOS subjects differs between Europe and the USA. In Sardinia, the incidence of 
obesity is lower than throughout the rest of Italy, with only 3-4% of high school female 
population presenting a BMI >25 (25). A combination of genetic factors, different lifestyle 
and diet are likely involved. In view therefore of the regional peculiarity, the patient 
population attending our Clinic was deemed to be of interest. 
Therefore it is important to understand the relationship between lipid pattern and BMI, 
hyperinsulinemia and/or insulin resistance and circulating androgens in adolescent PCOS. 
In a study carried out in July 2005 to the Adolescent Center for gynecological diseases of the 
Department of Obstetrics and Gynecology, University of Cagliari, San Giovanni di Dio 
Hospital seventy-one adolescent (age 13-18) subjects affected by PCOS were recruited for 
this study. On the basis of the various aspects linking PCOS dyslipidemia and CVD risk, the 
present study was designed to investigate the influence of BMI and insulin metabolism 
derangement on lipid levels. All subjects were screened for other causes of 
hyperandrogenism, such as androgen secreting tumors and congenital adrenal hyperplasia 
(tested by evaluation of 17- dydroxyprogesterone). All subjects were euthyroid and devoid 
of hyperprolactinemia, diabetes mellitus and cardiovascular disease. No subjects had taken 
hormonal contraceptives or other type of medication or been on a diet that may have 
affected lipid profile, carbohydrate metabolism or insulin levels for at least 3 months 
preceding the study. No subjects were either smokers or drinkers. No subjects practiced 
sports on a regular basis (3 or more 20-min sessions of aerobic exercise per week). 
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These patients were linked with a control group consisting of healthy patients referred to 
the Adolescent centre for ultrasound screening of ovarian disease. 
Control subjects and PCOS were studied 5 to 8 days following menstrual bleeding, which 
was progestin-induced in amenorrhoic patients. All patients were studied at least 15 days 
following Medrossi-Progesteron-Acetate administration (MAP 10 mg for 5 days). At the 
time of admittance to the study the presence of a dominant follicle, recent ovulation, or 
luteal phase was excluded by ultrasound examination and serum P evaluation. Height and 
weight were measured on the morning of testing. Waist and hip circumference were 
measured as previously referred. Blood pressure was measured in the second position and 
in the right arm (26) after 15 minutes resting.The hormonal study (after 12 hours overnight) 
included baseline plasma determination of LH, FSH, Estradiol (E2), Androstenedione (A), 
Testosterone (T), Dehydroepiandrosteronesulphate (DHEAS), 17hydroxyprogesterone (17-
OHP) and Sex-hormone-binding globulin (SHBG). Lipid assay was performed to measure 
total cholesterol level, high-density lipoprotein cholesterol level (HDL), low-density 
lipoprotein cholesterol level (LDL) and triglyceride level. Homocysteine levels were also 
determined. 
Adolescents meeting three or more of the following criteria were diagnosed with MBS: waist 
circumference of at least 90th percentile for age and gender; systolic or diastolic blood 
pressure at least 90th percentile for age, height and gender; fasting TG at least 110mg/dl 
(90th percentile for age); fasting HDL not exceeding 40mg/dl (10th percentile for age); and 
fasting glucose at least 110mg/dl. 
Subsequently, patients underwent a 75-g oral glucose tolerance test (OGTT). Insulin, C-
peptide, and glucose serum concentrations were analyzed prior to (time 0) and 30, 60, 90, 
120 and 180 min after oral glucose load. A normal glycemic response to OGTT was defined 
according to the criteria of the National Diabetes Data Group (27). Insulin, C-peptide and 
glucose response to glucose load were expressed as area below the curve (AUC), calculated 
according to the trapezoidal rule. The homeostatic index of IR (HOMA) was calculated as 
follows: HOMA = [fasting insulin (μU/ml) x fasting glucose (mmol/L/22, 5)]. (28) The body 
mass index (BMI) was calculated according to the following formula: body weight in 
kilograms/ height in m2. Normal weight was considered as 18 ≤ BMI ≥ 25. The degree of 
hirsutism was quantified using Ferriman and Gallwey (F-G) score (28). 
No differences were observed with regard to the presence of overweight and obese subjects 
between PCOS and controls (30% vs. 23%); a similar finding was obtained also for waist 
measurement and WHR, confirming that obesity is not a common finding in young PCOS 
subjects in the population studied.Moreover, no subjects affected by metabolic Syndrome or 
diabetes either among PCOS or in the control group were detected. No differences were 
revealed in lipid levels between PCOS and controls. In addition, no differences were 
reported for any of the fasting metabolic parameters (i.e. Glucose fasting insulin, HOMA 
ratio), whilst a higher insulin response under OGTT was obtained for PCOS subjects. On the 
other hand, statistical correlations clearly demonstrated the influence produced by BMI and 
waist measurement on HDL, triglyceride and LDL levels. However, dividing the population 
into tertiles for BMI and waist measurement significant differences were revealed for both 
HDL and LDL levels in lean overweight and obese subjects and in relation to the presence of 
visceral fat.The above features have also been reported by several authors carrying out 
studies on young subjects. 
Glueck published a study regarding PCOS and regular cycling adolescents in USA 
demonstrating a higher prevalence of obesity and dyslipidemia in PCOS. 
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However, when subjects were matched one-by-one for BMI and age, differences in lipids 
were no longer significant. In a recent paper on young obese subjects Shroff failed to 
demonstrate any difference in lipid as well as traditional CV factors in PCOS and control 
populations, but demonstrated a higher BMI in subjects presenting subclincal coronary 
atherosclerosis (CAC) (10). In young subjects from southern Italy, Orio demonstrated 
normal lipid levels in lean PCOS even in the presence of increased dimensions of heart 
ventricles.The above findings all seem to indicate that rather than being an insulin-
correlated factor BMI may well be implicated in lipid alteration. On the other hand, the 
presence of increased waist measurements in PCOS population suggests that the presence of 
visceral fat may represent an additional risk factor, independent from BMI in PCOS. The 
influence of insulin on lipid profile was also determined. 
Indeed, to date very few authors have investigated this aspect: Mather found a significant 
increase in traditional CV risk factors in PCOS women with fasting hyperinsulinemia in 
respect to their normoinsulinemic counterparts; this difference persisted when BMI was 
included as covariate. (29) Through reduction of hyperinsulinemia by means of metformin 
treatment Banazewska obtained a significant increase of HDL and reduction of triglycerides 
in a group of 43 adult PCOS. Our group recently published a paper on the peculiar insulin 
derangement observed in a population of normal weight young PCOS demonstrating a low 
incidence of insulin resistance but high incidence of hyperinsulinemia under OGTT (30). 
This peculiar metabolic alteration was confirmed in the present sample, thus allowing the 
separation of hyperinsulinemia from peripheral insulin resistance in data analysis. 
Ibanez et al. also demonstrated higher serum insulin levels after OGTT with normal insulin 
sensitivity in a population of adolescent girls with PCOS. The causes underlying the 
increased response of β-cells in these subjects are, as yet, unknown. It is not clear whether 
high levels of insulin necessarily indicate the presence of a disorder although it may be 
hypothesized that adaptation to the chronic risk of hypoglycemia in hyperinsulinemic 
subjects could lead to IR after some time. Moreover, our group recently demonstrated that a 
normal HOMA score is not sufficient to exclude earlymetabolic abnormalities such as 
hyperinsulinemia in young lean PCOS subjects. Hyperinsulinemia per se could contribute 
toward onset of hyperandrogenism independently of peripheral IR.(12) 
In this study was found a significant negative correlation between HDL and fasting insulin 
and HOMA, but this correlation was no longer significant when the influence of BMI was 
excluded, whereas insulin AUC was not related to any lipid parameters. 
Furthermore, although the PCOS sample studied here was divided into tertiles on the basis 
of both insulin resistance and insulin AUC levels, the data obtained clearly indicate the 
failure to detect any relationship between insulin levels and lipid profile. Nevertheless, 
surprisingly a positive correlation was observed between A levels and HDL and a negative 
correlation between A and triglycerides. Reports present in literature did not afford any 
explanation for this result. A negative effect of A on HDL levels has previously been 
reported in males to whom A supplements had been administered (31). Moreover, 
exogenous T is reported to influence negatively HDL via hepatic lipase (HL) (31) an enzyme 
that increases the clearance of HDL. Less is known about the regulation of HDL by 
endogenally-derived androgens. A study performed in women with PCOS was not able to 
demonstrate any correlation between T and HDL. Considerable controversy exists as to the 
effect of androgens on lipoprotein lipase (LPL) activity. 
In obese women LPL activity correlated positively with plasma free testosterone (32), 
whereas in women with PCOS a correlation with LPL activity was demonstrated. 
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Other authors have attributed to coexisting (29) insulin resistance the negative effect of 
androgen observed on lipid profile. In this case, the low incidence of insulin resistant 
subjects in a population may explain this unexpected result. 
In conclusion, no lipid differences were revealed between our population of adolescent 
PCOS from southern Italy and controls. 
Anthropometric characteristics (BMI, waist measurement and WHR) are the main 
parameters correlated to lipid derangement, confirming the importance of treating obesity at 
an early age to prevent onset of complex metabolic syndromes in the future. The latter may 
be of particular importance in PCOS populations in which insulin alterations 
(hyperinsulinemia and insulin resistance) are well known peculiarities potentially capable of 
influencing the long-term evolution of this endocrine disorder towards CVD and diabetes 
mellitus. A targeted support program should be set up for these young patients aimed at 
altering life style with the specific aim of reducing BMI and preventing onset of 
dyslipidemia. 
 
 
PCOS 
(n°71 ) 
CONTROLLI 
(n°94) 
P 
Age (years) (M±ES) (range 13-19) 18,61 ± 0,4 18,10 ± 0,38 NS 
BMI (kg\m2) (M±ES) 23,97 ± 0,72 22,56 ± 0,50 NS 
Overweight (BMI 25 - 29) (%) 10% 11%  
Obesity (BMI > 29) (%) 20% 13%  
Waist (cm) (M±ES) 78,60 ± 1,79 75,56 ± 1,18 NS 
WHR (M±ES) 0,77 ± 0 0,77 ± 0 NS 
Hirsutism (score F&G) (M±ES) 11,24 ± 0,67 6,7 ± 0,45 0,005° 
LH (IU/L)(M±ES) 5,21 ± 0,55 4,19 ± 0,36 NS 
FSH (IU/L)(M±ES) 6,42 ± 0,63 5,96 ± 0,19 NS 
E2 (pmol/L)(M±ES) 129,30 ± 20,58 136,81 ± 13,25 NS 
A (nmol/L)(M±ES) 0,08 ± 0 0,05 ± 0 0,005° 
Tot T(nmol/L)(M±ES) 0,02 ± 0 0,01 ± 0 0,005° 
17OHP (ng/mL)(M±ES) 1,49 ± 0,18 1,18 ± 0,07 NS 
DHEAS (μmol/L)(M±ES) 2,05 ± 0,12 1,6 ± 0,09 NS 
SHBG (nmol/L)(M±ES) 65,83 ± 4,54 71,18 ± 3,35 NS 
°P < 0,05 
Table 1. Shows the clinical and hormonal characteristics of PCOS population vs. Control 
group. No significant differences were revealed in age, body weight, waist and WHR 
between PCOS and control group. Likewise, no differences were observed in the incidence 
of overweight or obesity in the two groups. As expected, the prevalence of hirsutism and 
circulating androgen levels were higher amongst PCOS. 
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PCOS 
(n° 71) 
CONTROLLI 
(n°94) 
P 
Fasting Glucose 
(mmol/L)(M±ES) 
81,13 ± 0,65 88,00 ± 3,27 NS 
Fasting Insulin  
(pmol/L)(M±ES) 
119,98 ± 6,14 96,68 ± 4,73 NS 
HOMA (M±ES) 61,02 ± 3,09 57,81 ± 2,41 NS 
I-AUC 180 min 
(UI/ml)(M±ES) 
21069 ± 978,39 16578 ± 729,37 0,05 
Cholesterol  
(mg/dl)(M±ES) 
166,48 ± 3,53 169,51 ± 2,62 NS 
HDL-Cholesterol 
(mg/dl)(M±ES) 
54,26 ± 1,44 51,25 ± 0,89 NS 
LDL-Cholesterol  
(mg/dl)(M±ES) 
96,78 ± 3,08 104,55 ± 2,34 NS 
Cholesterol/ HDL 
(mg/dl)(M±ES) 
3,16 ± 0,09 3,37 ± 0,07 NS 
Triglycerides  
(mg/dl)(M±ES) 
73,91 ± 3,75 78,35 ± 3,86 NS 
Homocysteine  
(mol/L) (M±ES) 8,16 ± 0,20 7,68 ± 0,25 NS 
PCR (M±ES) 2,04 ± 0,36 0,89 ± 0,11 NS 
 
° P < 0,05 
Table 2. Reports the metabolic features of PCOS and control group. Fasting metabolic 
indexes detected for glucose, insulin and HOMA were similar between the two groups. On 
the contrary, insulin secretion after glucose load (I-AUC) was significantly higher in PCOS 
subjects. Total cholesterol, HDL, LDL, triglycerides and homocysteine levels did not differ 
between PCOS and control groups 
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 Cholesterol LDL-
Cholesterol 
HDL-
Cholesterol 
Triglycerides 
BMI (kg\m2) R = 0,0727 R = 0,2579٠ R = - 0,404▪ R = 0,1576 
WAIST (cm) R = 0,0869 R = 0,2960٠ R = - 0,5934▪ R = 0,1704 
WHR (cm) R = 0,1645 R = 0,2872٠ R = - 0,1853 R = 0,1362 
A (nmol/L) R = 0,0136 R = - 0,0523 R = 0,3705▪ R = -0,2948٠ 
Tot T (nmol/L) R = - 0,1016 R = - 0,0948 R = 0,0012 R = - 0,0157 
FSH (mIU/L) R = - 0,0134 R = - 0,0143 R = 0,0623 R = - 0,0687 
E2(pmol/L) R = - 0,1011 R = - 0,0895 R = 0,0698 R = - 0,1984 
DHEAS (μmol/L) R = - 0,0498 R = - 0,0022 R = - 0,0447 R = - 0,0441 
HOMA R = 0,0762 R = 0,1770 R = -0,3335 R = - 0,0214 
I-AUC 180 min(UI/ml) R = - 0,0098 R = - 0,0272 R = - 0,0701 R = - 0,0287 
SHBG (nmol/L) R = - 0,0689 R = - 0,1514 R = 0,1102 R = 0,1013 
17OHP (nmol/L) R = 0,0418 R = 0,0582 R = 0,0854 R = - 0,1720 
Homocysteine (mol/L) R = - 0,0670 R = - 0,0786 R = 0,0463 R = - 0,1108▪ 
Fasting Glucose R = 0,0049 R = 0,0260 R = -0,0829 R = 0,0643 
Fasting Insulin R = 0,0586 R = 0,1557 R = -0,3314 R = -0,0174 
P < 0,05 
P < 0,01 
P < 0,001 
Table 3. Illustrates linear regression relationship featured between lipid and physical, 
hormonal and metabolic parameters. Total cholesterol levels were significantly related to 
WHR but not to other antropometric parameters. On analyzing cholesterol fractions LDL 
levels were found to correlate positively with BMI, Waist, WHR and HOMA but not with I-
AUC. HDL results correlated in a markedly negative manner with the same physical 
parameters as BMI, WHR and waist circumference. Moreover, HDL was negatively 
correlated with both fasting insulin and HOMA but not I-AUC. Finally, HDL was positively 
correlated with circulating A and negatively with circulating T levels. 
Triglycerides appeared to correlate positively with BMI, Waist and WHR, and negatively 
with A levels. Homocysteine levels correlated positively with plasma triglyceride content. In 
view of the potential capacity of BMI to affect insulin sensitivity, conditional regression 
analysis was performed on HOMA and lipid assays to exclude any possible influence of 
BMI: HOMA resulted as being no longer correlated with any lipid parameter.To determine 
whether lipid alterations were primarily caused by increased BMI, lipid assay was repeated 
stratifying the population into 3 weight categories: normal weight, overweight and obese, 
and waist measurements were classified (normal and excessive). 
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Fig. 1. Shows the lipid levels in relation to the BMI and the waist of PCOS group.Normal 
weight and normal waist subjects featured lower LDL and Higher HDL compared to 
increased waist overweight or obese counterparts. On the other hand, in order to evaluate 
the influence of metabolic alteration subjects were also stratified on the basis of both HOMA 
and Insulin AUC values (fig.2). 
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Fig. 2. Shows lipid levels in subjects divided into tertiles for both HOMA and Insulin AUC 
levels. Similar lipid values were demonstrated in all subjects. 
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 Cholesterol 
LDL-
Cholesterol 
HDL-
Cholesterol 
Triglycerides 
BMI (kg\m2) R = 0,0800 R = - 0,0017 R = - 0,4762▪ R = 0,6962 
WAIST (cm) R = 0,1410 R = 0,0753 R = - 0,4253▪ R = 0,6765 
WHR (cm) R = 0,0326 R = - 0,1535 R = - 0,1878 R = 0,4262 
A (nmol/L) R = - 0,1921 R = - 0,0280 R = - 0,1845 R = 0,0007 
Tot T (nmol/L) R = - 0,3425 R = - 0,4544▪ R = - 0,1377 R = 0,3692 
FSH (IU/L) R = 0,3094 R = 0,3909▪ R = 0,3711▪ R = - 0,1603 
E2(pmol/L) R = 0,0150 R = 0,0124 R = - 0,0264 R = - 0,0876 
DHEAS (μmol/L) R = 0,1230 R = 0,1925 R = - 0,1793 R = 0,2206 
SHBG (nmol/L) R = - 0,2226 R = - 0,2834 R = 0,0655 R = - 0,0942 
17OHP (nmol/L) R = - 0,0925 R = - 0,0586 R = 0,1667 R = - 0,3703▪ 
HOMA R = 0,4724 R = 0,5140 R = 0,2293 R = - 0,0123 
I-AUC 180 
min(UI/ml) 
R = - 0,0021 R = 0,0331 R = - 0,3391 R = 0,2882 
Homocysteine 
(mol/L) R = 0,2148 R = 0,1214 R = - 0,2604 R = 0,5656▪ 
Fasting Glucose R = 0,0440 R = 0,1325 R = - 0,1952 R = - 0,0396 
Fasting Insulin R = 0,1226 R = 0,1315 R = 0,0435 R = 0,0972 
 
P < 0,05 
P < 0,01 
P < 0,001 
Table 4. Linear relationships between lipid assays and phisical endocrine and metabolic 
parameters in CONTROLS. 
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Cholesterol 
LDL-
Cholesterol 
HDL-
Cholesterol 
Triglycerides 
BMI (kg\m2) R = 0,1058 R = 0,2252 R = - 0,3930 R = 0,2933 
WAIST (cm) R = 0,1298 R = 0,2624 R = -0,3756 R = 0,2856 
WHR (cm) R = 0,2174 R = 0,3039 R = - 0,1924 R = 0,2063 
E2(pmol/L) R = - 0,0912 R = - 0,0912 R = 0,0541 R = - 0,1495 
A (nmol/L) R = - 0,0401 R = - 0,0953 R = 0,2933 R = -0,2400 
Tot T (nmol/L) R = - 0,1848 R = - 0,2191 R = 0,0181 R = 0,0085 
SHBG (nmol/L) R = - 0,1260 R = -0,1973 R = 0,1038 R = 0,0368 
Fasting Glucose R = 0,0107 R = 0.0800 R = - 0,1425 R = -0,0092 
Fasting Insulin R = 0,0773 R = 0,1239 R = - 0,1960 R = 0,0109 
HOMA R = 0,1349 R = 0,2269 R = - 0,2800▪ R = 0,0021 
I-AUC 180 min(UI/ml) R = 0,0324 R = 0,0550 R = - 0,0930 R = 0,0123 
Homocysteine (mol/L) R = 0,0764 R = 0,0209 R = - 0,0656 R = 0,2863▪ 
P < 0,05 
P < 0,01 
P < 0,001 
Table 5. Linear relationships between lipid assays and phisical endocrine and metabolic 
parameters in all patients. 
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